Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price objective cut by JPMorgan Chase & Co. from €51.00 ($52.58) to €23.00 ($23.71) in a report published on Monday morning, The Fly reports.
Several other equities research analysts also recently weighed in on FMS. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an underperform rating to a buy rating and upped their target price for the stock from $30.30 to $33.70 in a research note on Monday, June 27th. DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a hold rating in a research note on Friday, July 29th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a research note on Friday, July 29th. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a buy rating in a research note on Friday, July 15th. Finally, Truist Financial cut their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a hold rating on the stock in a research note on Wednesday, June 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of Hold and a consensus price target of $49.01.
Get Fresenius Medical Care AG & Co. KGaA alerts:Fresenius Medical Care AG & Co. KGaA Price Performance
Fresenius Medical Care AG & Co. KGaA stock opened at $18.44 on Monday. The company's 50 day simple moving average is $24.60 and its 200-day simple moving average is $29.72. The company has a market capitalization of $10.81 billion, a price-to-earnings ratio of 11.75, a price-to-earnings-growth ratio of 0.85 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $18.16 and a 1 year high of $40.85. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.93 and a current ratio of 1.18.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.08. The business had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.97 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.42% and a return on equity of 6.70%. As a group, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.79 earnings per share for the current year.Institutional Inflows and Outflows
Several large investors have recently modified their holdings of FMS. Russell Investments Group Ltd. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at $1,152,000. Janney Montgomery Scott LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 7.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 31,996 shares of the company's stock worth $1,039,000 after purchasing an additional 2,114 shares during the period. Commonwealth Equity Services LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 6.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company's stock worth $440,000 after purchasing an additional 817 shares during the last quarter. Yousif Capital Management LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $295,000. Finally, Riverwater Partners LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at $325,000. Institutional investors and hedge funds own 4.73% of the company's stock.
About Fresenius Medical Care AG & Co. KGaA
(Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- 3 Hotel Stocks to Consider Checking into After Earnings
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- Time To Take A Serious Look At Nikola Stock As Production Starts
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.